Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

JTT 608

Known as: JTT-608 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
INHIBITORS FOR THE TREATMENT OF DABETES
  • 2017
    • Corpus ID: 55583882
Diabetes Research Foundation, “Diabetes and Your Eyesight.” printed from http://www.glaucoma.org/learn? diabetes and yo. html, 2… Expand
  • figure 7
  • table III
  • figure 1
2005
2005
Daily inhibition of postprandial hyperglycaemia with JTT‐608, a novel oral antidiabetic agent, ameliorates pancreatic function in neonatally streptozotocin‐treated rats
Aim:  Chronic glycaemic control, in particular, the control of postprandial hyperglycaemia, is essential for preventing the… Expand
2003
2003
Antidiabetic effect of chronic administration of JTT-608, a new hypoglycemic agent, in diabetic Goto-Kakizaki rats.
We investigated the chronic effect of a new antidiabetic agent, trans-4-(methylcyclohexyl)-4-oxobutyric acid (JTT-608), in Goto… Expand
2001
2001
A novel enhancer of insulinotrophic action by high glucose (JTT-608) stimulates insulin secretion from pancreatic beta-cells via a new cellular mechanism.
Insulin secretion from MIN6 cells (a pancreatic beta-cell line) induced by high glucose (greater than 16.8 mM) was potentiated by… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
2001
2001
A new hypoglycemic agent, JTT-608, evokes protein kinase A-mediated Ca(2+) signaling in rat islet beta-cells: strict regulation by glucose, link to insulin release, and cooperation with glucagon-like…
A new nonsulfonylurea oral hypoglycemic agent, JTT-608, has been reported to stimulate insulin release at elevated, but not low… Expand
2000
2000
The insulinotropic mechanism of the novel hypoglycaemic agent JTT‐608: direct enhancement of Ca2+ efficacy and increase of Ca2+ influx by phosphodiesterase inhibition
We examined the effects of the novel hypoglycaemic agent JTT‐608 [trans‐4‐(4‐methylcyclohexyl)‐4‐oxobutyric acid] on insulin… Expand
1999
1999
JTT‐608 restores impaired early insulin secretion in diabetic Goto‐Kakizaki rats
We investigated the pharmacological effects of a new antidiabetic agent, JTT‐608, in comparison with the sulphonylurea… Expand
1999
1999
JTT-608 controls blood glucose by enhancement of glucose-stimulated insulin secretion in normal and diabetes mellitus rats.
We investigated the pharmacological effects of a new anti-hyperglycemic agent, JTT-608 [trans-4-(4-methylcyclohexyl)-4-oxobutyric… Expand
1999
1999
Glucose-dependent insulinotropic effects of JTT-608, a novel antidiabetic compound.
The effects of JTT-608 [trans-4-(4-methylcyclohexyl)-4-oxobutyric acid], a novel antidiabetic compound, on insulin secretion were… Expand
1998
1998
4-(trans-4-Methylcyclohexyl)-4-oxobutyric acid (JTT-608). A new class of antidiabetic agent.
During an investigation of drugs for improving the beta-cell response to glucose, we found that 4-cyclohexyl-4-oxobutyric acid… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE